On Thursday, GlaxoSmithKline announced that it entered into a collaboration agreement to obtain exclusive rights to AFFiRiS' vaccine programmes targeting beta-amyloid for the treatment of Alzheimer's disease. The deal could be worth as much as 430 million euros ($553 million) if the compounds are successfully commercialised.
Under the deal, the UK company is gaining development and commercialisation rights to two early-stage vaccine candidates based on AFFiRiS' AFFiTOPE technology, as well as an option to develop and commercialise alternative vaccine candidates that are currently in preclinical development. AFFiRiS will receive an upfront payment of 22.5 million euros ($29 million) and could be eligible for future milestone payments and royalties.
To read more Top Story articles, click here.